October 16, 2017
BioPolicy Summit 2017 – Improving Reproducibility of Research Through Digital Tools, Technologies, and Laboratory Automation
In 2017, GBSI’s BioPolicy Summit was themed around a new initiative to improve the reproducibility in life science research, Laboratory Automation. The meeting brought together biologists, programmers, instrumentation manufacturers, the maker community, journals and funders – to examine innovations that are redefining the laboratory environment and new technologies that will help make research more reproducible.
September 25, 2016
Antibody Validation: Standards, Policies, and Practices
In 2016 at Asilomar, GBSI in conjunction with The Antibody Society, brought together key stakeholders from academia, antibody producers, pharma, funders, and journals to share perspectives and contribute to tangible solutions for validating research antibodies.
February 9, 2016
BioPolicy Summit 2016 – Research Reproducibility: Innovative Solutions to Drive Quality
The 2016 Summit—Research Reproducibility: Innovative Solutions to Drive Quality—welcomed premiere life science thought leaders, including top scientists and policy makers from NIH, science societies, foundations, journals and industry to discuss the complex challenges of irreproducibility and propose workable solutions. GBSI’s challenge to the bio-research community, Reproducibility2020 was introduced.
November 13, 2014
BioPolicy Summit 2014 – Transforming Cancer Research Through Cell Authentication
The 2014 Inaugural Summit focused on cancer research by recognizing the transformative impact cell authentication can have in improving cancer study replication. Key recommendations developed by GBSI’s Cell Authentication and Standards Task Force were discussed, including the role public and private funders can have on improving the quality and efficacy of research.
October 1, 2013
2013 Biotechnology & Standards Conference with the MIT Center for Biomedical Information
2013 Biotechnology & Standards Conference–The Prospects for a Life Sciences Standards Revolution, brought together over 80 academic biologists, biopharma executives, economists, legal and standards experts, and policymakers to discuss the need for standards in preclinical research. GBSI published its seminal report, “The Case for Life Science Standards” shortly thereafter.